<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004103</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067322</org_study_id>
    <secondary_id>P30CA016087</secondary_id>
    <secondary_id>NYU-9822</secondary_id>
    <secondary_id>P-UPJOHN-647597196</secondary_id>
    <secondary_id>NCI-G99-1594</secondary_id>
    <nct_id>NCT00004103</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer</brief_title>
  <official_title>A Phase II Study of Systemic Therapy With CPT-11 (Camptosar HCl) and Cisplatin in Patients With Advanced Gastric Cancer to be Followed by Surgical Resection and Postoperative Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug and combining chemotherapy with&#xD;
      surgery may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed by&#xD;
      surgery, floxuridine, and cisplatin work in treating patients with stomach cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete and partial response rates and time to treatment failure in&#xD;
           patients with advanced gastric cancer treated with neoadjuvant irinotecan and cisplatin&#xD;
           followed by surgery then intraperitoneal floxuridine and cisplatin.&#xD;
&#xD;
        -  Determine the rate of potentially curative surgery in patients receiving this regimen.&#xD;
&#xD;
        -  Determine the toxicity and tolerance of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive cisplatin IV and irinotecan IV once a week for 4 weeks. This course&#xD;
      is repeated 2 weeks later.&#xD;
&#xD;
      Patients who achieve complete or partial remission or stable disease undergo resection 4&#xD;
      weeks after the last chemotherapy dose.&#xD;
&#xD;
      Patients with no residual macroscopic disease begin adjuvant intraperitoneal (IP)&#xD;
      chemotherapy 1 week after surgery. Chemotherapy consists of floxuridine IP over 30 minutes on&#xD;
      days 1-3 and days 22-24 and cisplatin IP on days 3 and 24.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-33 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>floxuridine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven, previously untreated gastric cancer&#xD;
&#xD;
               -  Stage IB, II, III, or IV (T3-4, N0 OR any T, N1-2, M0)&#xD;
&#xD;
               -  No metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times ULN&#xD;
&#xD;
          -  PT, aPTT, and TT normal&#xD;
&#xD;
          -  No Gilbert's disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN no greater than 30 mg/dL&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No congestive heart failure requiring therapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other invasive malignancy in the past 5 years except adequately treated basal or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other severe concurrent disease&#xD;
&#xD;
          -  No psychiatric disorders that would preclude compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for gastric cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for gastric cancer&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior surgery for gastric cancer&#xD;
&#xD;
          -  No emergent need for surgery for gastrointestinal obstruction, perforation, or&#xD;
             hemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Newman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Newman E, Potmesil M, Ryan T, Marcus S, Hiotis S, Yee H, Norwood B, Wendell M, Muggia F, Hochster H. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Semin Oncol. 2005 Dec;32(6 Suppl 9):S97-100. doi: 10.1053/j.seminoncol.2005.06.002.</citation>
    <PMID>16399443</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2011</last_update_posted>
  <keyword>stage I gastric cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

